Biogen (BIIB) grants 10,560 restricted stock units to Head of Development

Rhea-AI Filing Summary

Singhal Priya reported acquisition or exercise transactions in this Form 4 filing.

BIOGEN INC. reported that Priya Singhal, Head of Development, received a grant of 10,560 restricted stock units. These RSUs were awarded at no cash cost per unit as part of equity compensation. According to the disclosure, the units vest in three equal yearly installments beginning on the first anniversary of the February 13, 2026 grant date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Singhal Priya

Role Head of Development

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Unit	10,560	$0.00	--

Holdings After Transaction: Restricted Stock Unit — 10,560 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Singhal Priya

(Last) (First) (Middle)

225 BINNEY

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOGEN INC. [ BIIB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Head of Development

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	$0	02/13/2026		A		10,560		(1)	02/13/2029	Common Stock	10,560	$0	10,560	D

Explanation of Responses:

1. The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026.

	/s/ Wendell Taylor, attorney-in-fact for Priya Singhal	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Biogen (BIIB) report for Priya Singhal?

Biogen reported that Head of Development Priya Singhal received a grant of 10,560 restricted stock units. The grant reflects equity-based compensation and involves no cash purchase, aligning her interests with shareholders through potential future share ownership after the vesting schedule is satisfied.

How many restricted stock units were granted to Biogen executive Priya Singhal?

Priya Singhal was granted 10,560 restricted stock units in a single equity award. This entire amount is subject to a multi-year vesting schedule, meaning the units become earned and settle over time rather than immediately on the February 13, 2026 grant date.

What is the vesting schedule for Priya Singhal’s Biogen restricted stock units?

The 10,560 restricted stock units vest in three equal yearly installments. Vesting begins on the first anniversary of the February 13, 2026 grant date, so one-third becomes earned each year over three years, encouraging longer-term alignment with Biogen’s performance and retention.

Did Priya Singhal buy or receive Biogen (BIIB) shares in this Form 4?

Priya Singhal received an award of restricted stock units rather than buying shares on the market. The transaction is coded as a grant or other acquisition, reflecting equity compensation that vests over time instead of an immediate open-market purchase of Biogen stock.

What role does Priya Singhal hold at Biogen in this insider filing?

In this insider transaction, Priya Singhal is identified as an officer serving as Head of Development. The reported grant of 10,560 restricted stock units represents part of her compensation package, linking a portion of her potential future pay to Biogen’s share performance.